Business Description
Ocular Therapeutix Inc
NAICS : 325412
SIC : 2834
ISIN : US67576A1007
Total Employee Number:
325Description
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 8.39 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.14 | |||||
Debt-to-EBITDA | -0.29 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 6.4 | |||||
Beneish M-Score | -2.97 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -23.7 | |||||
3-Year EBITDA Growth Rate | -21.2 | |||||
3-Year EPS without NRI Growth Rate | -7.4 | |||||
3-Year FCF Growth Rate | -14.8 | |||||
3-Year Book Growth Rate | 87.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 6.53 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 87.83 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 58.06 | |||||
9-Day RSI | 60.64 | |||||
14-Day RSI | 60.01 | |||||
3-1 Month Momentum % | -0.57 | |||||
6-1 Month Momentum % | -22.38 | |||||
12-1 Month Momentum % | -21.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 14.81 | |||||
Quick Ratio | 14.73 | |||||
Cash Ratio | 13.98 | |||||
Days Inventory | 187.94 | |||||
Days Sales Outstanding | 198.36 | |||||
Days Payable | 318.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -40.9 | |||||
Shareholder Yield % | -0.09 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 87.24 | |||||
Operating Margin % | -575.42 | |||||
Net Margin % | -558.24 | |||||
EBITDA Margin % | -527.01 | |||||
FCF Margin % | -463.02 | |||||
OCF Margin % | -434.69 | |||||
ROE % | -70.31 | |||||
ROA % | -51.71 | |||||
ROIC % | -1186.09 | |||||
3-Year ROIIC % | -2770.17 | |||||
ROC (Joel Greenblatt) % | -1283.27 | |||||
ROCE % | -54.04 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 38.69 | |||||
PB Ratio | 3.84 | |||||
Price-to-Tangible-Book | 3.84 | |||||
EV-to-EBIT | -5.91 | |||||
EV-to-EBITDA | -6.01 | |||||
EV-to-Revenue | 31.7 | |||||
EV-to-Forward-Revenue | 31.39 | |||||
EV-to-FCF | -6.85 | |||||
Price-to-GF-Value | 2.33 | |||||
Price-to-Median-PS-Value | 0.8 | |||||
| Price-to-Net-Current-Asset-Value | 4.02 | |||||
| Price-to-Net-Cash | 4.33 | |||||
Earnings Yield (Greenblatt) % | -16.92 | |||||
FCF Yield % | -10.77 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:OCUL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ocular Therapeutix Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 52.038 | ||
| EPS (TTM) ($) | -1.46 | ||
| Beta | 2.1371 | ||
| 3-Year Sharpe Ratio | 0.54 | ||
| 3-Year Sortino Ratio | 1.28 | ||
| Volatility % | 40.63 | ||
| 14-Day RSI | 60.01 | ||
| 14-Day ATR ($) | 0.55552 | ||
| 20-Day SMA ($) | 9.701 | ||
| 12-1 Month Momentum % | -21.12 | ||
| 52-Week Range ($) | 6.2301 - 16.44 | ||
| Shares Outstanding (Mil) | 218.96 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ocular Therapeutix Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ocular Therapeutix Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 08:00 | In 116 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 115 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 08:00 | In 25 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 24 days | ||
| HC Wainwright 6th Annual Ophthalmology Virtual Conference | 2026-07-22 16:30 | In 11 days | ||
| Analyst meeting for 2026 | 2026-06-17 14:00 | 8.94 (-0.56%) | ||
| General meeting for 2026 | 2026-06-10 08:30 | 8.47 (+2.29%) | ||
| Guidance call for 2026 | 2026-05-26 14:30 | 8.23 (+0.00%) | ||
| Guidance call for 2026 | 2026-05-12 15:40 | 9.28 (-4.03%) | ||
| First quarter earnings conference call for 2026 | 2026-05-05 08:00 | 9.77 (+4.27%) |
Show
Entries
Ocular Therapeutix Inc Frequently Asked Questions
What is Ocular Therapeutix Inc(OCUL)'s stock price today?
The current price of OCUL is $10.22. The 52 week high of OCUL is $16.44 and 52 week low is $6.23.
When is next earnings date of Ocular Therapeutix Inc(OCUL)?
The next earnings date of Ocular Therapeutix Inc(OCUL) is 2026-08-05 Est..
Does Ocular Therapeutix Inc(OCUL) pay dividends? If so, how much?
Ocular Therapeutix Inc(OCUL) does not pay dividend.
Guru Commentaries on NAS:OCUL
No articles.
Press Release
Articles on Ocular Therapeutix Inc
Headlines
See More- 1
Jun 17, 2026
Ocular to submit Axpaxli NDA for wet AMD in Q4
Seeking Alpha • 8:04am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers